Re-treating anaplastic thyroid cancer that progressed on BRAF therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests if a second course of targeted therapy (dabrafenib and trametinib) combined with chemotherapy can help people with a specific type of aggressive thyroid cancer (BRAF-positive anaplastic thyroid cancer) whose tumors stopped responding to initial targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anaplastic thyroid cancer (a rare and fast-growing type) confirmed by a biopsy.
- Your cancer has a BRAF V600 gene mutation (a specific genetic change).
- Your cancer grew while you were on the targeted therapy combination dabrafenib + trametinib.
- Your cancer grew after at least one course of chemotherapy that included a taxane drug (like paclitaxel or docetaxel).
- You are 18 years or older and able to care for yourself (ECOG score 0-2).
- Your organs and bone marrow are working well enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a combination of two drugs, zanzalintinib and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer that has not spread to the brain or been treated with similar drugs. The study aims to see if this combination can help shrink or control the cancer.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.